John Garcia: Chairman, Independent Non-Executive Director
Mr. Garcia was appointed to the Board of the Company in September 2007. With a 25-year career in the health products industry, he has been instrumental In the development and growth of several medical products and services companies. He served for more than ten years as President of Sulzermedica’s US$300 million pacemaker business before it was acquired by Guidant in 1998. He also held sales and marketing management positions with FHP (a California HMO), Bio Science (a national reference lab) and Pharmaseal (a division of American Hospital Supply Corporation).
Klaas de Boer: Non-Executive Director
Mr. de Boer was appointed to the Board of the Company in September 2008. He has been operating at the intersection of technology, innovation and entrepreneurship in the U.S., Europe and Israel for the past 15 years. His career started with McKinsey & Company in Amsterdam in 1991. In 1997, he left consulting to launch a corporate venturing team for Baan Investment (later Vanenburg Group), a former client. He subsequently spent several years as an independent (angel) investor, adviser and interim manager with a range of entrepreneurial companies. In 2006, he joined the Entrepreneurs Fund, which he restructured, repositioned and now leads. In his capacity as Managing Partner, Mr. de Boer sits on the boards of several other life-sciences and medical-technology companies.
Andrew Clark: Senior Independent Non-Executive Director
Dr. Clark was appointed to the Board of the Company in September 2007. He received his Ph.D. in Neuroscience from St. Andrew's University and was a post-doctoral research fellow in pharmacology at the University of Oxford. He worked in London as a biotech analyst at Baring Securities. In 1995, Andrew co-founded Reabourne Ltd, an investment management business focused on small capitalization technology and biotechnology companies, acting as portfolio manager. He left Reabourne in 2003 following the sale of the business, and currently works as a consultant in the biotechnology field. He has held a number of non-executive directorships with life-science and investment companies.
David Kravitz: Executive Director CEO
Mr. Kravitz was a founder of the Company and has served as the Company’s senior executive since its inception in 1998. He is co-inventor of several of the group’s key proprietary technologies and patents and co-author of initial machine preservation-related scientific review papers and presentations. He is an active and respected member of the global transplant community, having led the Company from inception to its position as a world leading transplant technology company. Prior to starting LSI, Mr. Kravitz held senior executive roles in consulting and operating companies.
Dr. Steven Mayer: Non-Executive Director
Dr. Mayer was appointed to the Board of the Company in 2003. Both a physician and chemical engineer, he has spent more than 20 years in diagnostics, devices and pharmaceuticals. He held several positions with Abbott Laboratories, including Director of the Abbott Diagnostics Division and Pharmaceutical Products Division, and gained experience in a number of areas, including basic R&D, manufacturing, strategic planning, economics and outcomes research. Dr. Mayer currently serves as advisor and scientific consultant to various medical companies.
Eric Swenden: Non-Executive Director
Mr. Swenden was appointed to the Board of the Company in 2003. He has enjoyed a long and successful career in finance and company management, having held positions on the boards of several public companies, including Vandemoortele Food Group and General Bank (Belgium's largest bank before its merger with Fortis).